Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma

Title:Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma

Volume: 17

Author(s): Yunzhi Zhu, Yi Hu, Chengsheng Yang, Shipu Huang, Jianping Wen, Weiguo Huang and Shengjun Xiao*

Affiliation:

• Guangxi Key Laboratory of Tumor Immunity and Microenvironment Regulation, Guilin Medical University, Guilin 541199, China
• Department of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China

Abstract: Nasopharyngeal cancer is a rare cancer with unique ethnic and geographic distribution. Since nasopharyngeal cancer often originates from the pharyngeal crypt, early symptoms are not obvious. They are difficult to detect in time, and the disease is usually diagnosed and treated only when it has progressed to an advanced-stage. Since angiogenesis is essential for the growth and invasion of solid tumors, antiangiogenic therapy has become a common treatment strategy for many solid tumors, and it has also achieved remarkable results in the treatment of nasopharyngeal carcinoma, which is prone to recurrence and distant metastasis. In this paper, we review the latest research progress of antiangiogenic drugs for nasopharyngeal carcinoma and their antiangiogenic mechanism of action and further propose some promising antiangiogenic therapeutic targets.

Cite this article as:

Zhu Yunzhi, Hu Yi, Yang Chengsheng, Huang Shipu, Wen Jianping, Huang Weiguo and Xiao Shengjun*, Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma, Current Molecular Pharmacology 2024; 17 : e18761429290933 . https://dx.doi.org/10.2174/0118761429290933240408071812